Canada Markets closed

Kane Biotech Inc. (KNE.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.09500.0000 (0.00%)
At close: 03:36PM EDT
Full screen
Previous Close0.0950
Open0.1000
Bid0.0900 x 0
Ask0.0950 x 0
Day's Range0.0950 - 0.1000
52 Week Range0.0800 - 0.1900
Volume34,000
Avg. Volume18,354
Market Cap10.907M
Beta (5Y Monthly)0.30
PE Ratio (TTM)N/A
EPS (TTM)-0.0350
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Kane Biotech Announces Second Quarter 2022 Financial Results

    Significant Milestones AchievedWINNIPEG, Manitoba, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2022 financial results. Second Quarter Financial Highlights: Total revenue for the three months ended June 30, 2022 was $839,579, an increase of 201% compared to $278,741 in the three months ended June 30, 2021.License revenue in the three months ended June 30, 2022 was $500,225, an increase of 1,295%

  • GlobeNewswire

    Kane Biotech to Release Second Quarter 2022 Financial Results on August 25, 2022 – Conference Call to Follow

    WINNIPEG, Manitoba, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its second quarter 2022 financial results after market close on Thursday, August 25, 2022. Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and di

  • GlobeNewswire

    Kane Biotech Announces Adoption of Amended and Restated Stock Option Plan and Performance and Restricted Share Unit Plan

    Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, June 30, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces that, following the approval of the shareholders of the Company (the “Shareholders”) at the annual general and special meeting of Shareholders held on May 26, 2022, the Company adopted the second amended and restated stock option plan of the Company and the amended and restated perform